When will the CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER patents expire, and when will generic CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	020734-005	Sep 29, 1997		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

This analysis examines the market position and financial performance of CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, a parenteral nutrition (PN) solution. The product targets patients requiring intravenous nutritional support, particularly those with sulfite sensitivities or where sulfite presence is contraindicated. Key market drivers include the increasing prevalence of conditions necessitating PN, advancements in infusion technologies, and evolving reimbursement policies. The financial trajectory is influenced by manufacturing costs, generic competition, and the patent landscape.

What is the Primary Indication for CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER?

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER is indicated for use in parenteral nutrition. It provides a source of calories and protein to patients who are unable to ingest, digest, or absorb sufficient nutrients via the gastrointestinal tract. This includes patients with severe malnutrition, short bowel syndrome, or other conditions that impair oral or enteral feeding. The "sulfite-free" designation is critical for patients who exhibit hypersensitivity reactions to sulfites, which are commonly used as preservatives in some pharmaceutical products. The dextrose 25% component offers a concentrated carbohydrate source for caloric provision.

What are the Key Market Segments and Their Growth Drivers?

The market for parenteral nutrition solutions, including CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, is segmented by patient population, healthcare setting, and formulation type.

Patient Populations:

Oncology Patients: Patients undergoing cancer treatment often experience gastrointestinal toxicity, necessitating PN.
Gastrointestinal Disorders: Individuals with inflammatory bowel disease (Crohn's disease, ulcerative colitis), short bowel syndrome, or intestinal fistulas rely on PN for nutritional support.
Critical Care Patients: Critically ill patients in intensive care units (ICUs) frequently require PN due to prolonged inability to feed enterally.
Sulfite-Sensitive Patients: A niche but important segment comprising individuals with known sulfite allergies or sensitivities.

Healthcare Settings:

Hospitals: The primary setting for PN administration, particularly for acute care and inpatient settings.
Long-Term Care Facilities: Patients requiring extended PN support may transition to these facilities.
Home Healthcare: Increasing trend of home-based PN administration for chronic conditions, driven by cost-effectiveness and patient preference.

Formulation Types:

Two-in-One (2-in-1) Formulations: Combine amino acids and dextrose, with lipids administered separately.
Three-in-One (3-in-1) Formulations: Combine amino acids, dextrose, and lipids in a single admixture. CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER is a component solution that would be mixed with other components (amino acids, lipids, electrolytes, vitamins, trace elements) to create a complete PN formula, often a 3-in-1 admixture.

Growth Drivers:

Aging Global Population: Increased incidence of chronic diseases associated with aging that require nutritional support.
Rising Incidence of Chronic Diseases: Growing prevalence of diabetes, cancer, and gastrointestinal disorders globally.
Technological Advancements: Development of advanced infusion pumps and closed-system PN admixtures improves safety and ease of use.
Increased Awareness and Diagnosis: Greater recognition of the benefits of PN in managing complex medical conditions.
Home Parenteral Nutrition (HPN) Expansion: Favorable reimbursement policies and improved patient education facilitate HPN.

What is the Patent Landscape and Its Impact on Market Exclusivity?

The patent landscape for CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER is critical for understanding market exclusivity and the potential for generic entry. While the specific active ingredients (amino acids, dextrose) are well-established, patents may cover novel formulations, manufacturing processes, delivery systems, or specific combinations that enhance stability, efficacy, or patient safety.

Composition of Matter Patents: These are the strongest patents, protecting the unique chemical structure of a compound. For established ingredients like those in CLINIMIX, these are less likely to be the primary protection.
Formulation Patents: These patents cover specific ratios of ingredients, excipients, pH ranges, or stabilizers that improve the product's shelf life, solubility, or compatibility. The "sulfite-free" aspect itself could be a subject of formulation patents if it involves a novel method of achieving this stability without sulfites.
Process Patents: These protect specific methods of manufacturing the drug product, which can be difficult for generic manufacturers to circumvent.
Method of Use Patents: These patents protect specific therapeutic applications of the drug.

The expiration of key patents can pave the way for generic competition, leading to price erosion and a potential decline in market share for the branded product. Generic versions of PN components have become increasingly available, intensifying competition. The absence of sulfites in CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER may represent a key differentiator protected by intellectual property or a unique formulation characteristic that grants it a competitive edge in specific patient populations.

Example of Patent Impact (Hypothetical): If a patent on a novel stabilization technique for a sulfite-free PN formulation expires in 2025, generic manufacturers could launch bioequivalent products thereafter, potentially reducing the market share of branded solutions that relied on that patented technology for their sulfite-free status. The specific patent expiration dates relevant to CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER would require a detailed patent search.

What is the Competitive Landscape?

The market for parenteral nutrition is competitive, with several global manufacturers offering a range of PN solutions. CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER competes with both branded and generic products.

Key Competitors and Product Types:

Other Branded PN Component Manufacturers: Companies offering their own lines of amino acid solutions, dextrose solutions, and lipid emulsions. These may also include sulfite-free options or products with different dextrose concentrations or amino acid profiles. Examples of major players in the broader PN market include Baxter International, Fresenius Kabi, and Grifols.
Generic PN Component Manufacturers: A significant portion of the market is served by generic suppliers who offer lower-cost alternatives to branded components. These often include standard amino acid and dextrose solutions.
Ready-to-Use (RTU) PN Admixtures: Some companies offer fully compounded PN solutions, reducing the need for hospital pharmacies or infusion centers to mix components. While this is a different product category, it represents an alternative approach to PN delivery that can impact the demand for individual components.

Factors Influencing Competition:

Pricing: Generic competition exerts significant downward pressure on prices.
Product Differentiation: Unique formulations (like sulfite-free), improved stability, or specialized nutrient profiles can command premium pricing and market share.
Supply Chain Reliability: Consistent availability and robust supply chains are critical, especially for essential medical products.
Regulatory Approvals: Meeting stringent FDA (or equivalent) requirements for quality and safety is a prerequisite.
Reimbursement Policies: Payer coverage and reimbursement rates for PN products significantly influence market access and adoption.

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER's competitive advantage likely stems from its sulfite-free formulation, catering to a specific patient need not met by all competitors. The "2.75/25" designation refers to specific concentrations of amino acids and dextrose, indicating a particular blend designed for certain metabolic requirements, differentiating it from standard offerings.

What is the Financial Trajectory and Revenue Generation Model?

The financial trajectory of CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER is shaped by sales volume, pricing strategies, manufacturing costs, and market penetration.

Revenue Generation: The product is typically sold to hospitals, long-term care facilities, and specialty pharmacies. Revenue is generated through direct sales and distribution agreements. The pricing model for PN components is influenced by:

Cost of Goods Sold (COGS): This includes raw material costs (amino acids, dextrose, water for injection, excipients), manufacturing labor, energy, and packaging.
Branding and Intellectual Property: Branded products generally command higher prices than generics.
Market Dynamics: Competitive pricing pressures from generic alternatives.
Volume-Based Discounts: Larger orders may receive tiered pricing.
Reimbursement Rates: Payer reimbursement levels set a ceiling on what healthcare providers are willing to pay.

Financial Trajectory Factors:

Market Demand: Growth in the underlying market for PN is a primary driver of sales volume.
Generic Erosion: As patents expire or if similar sulfite-free alternatives emerge, pricing power may diminish, impacting revenue per unit.
Manufacturing Efficiency: Improvements in manufacturing processes can reduce COGS, thereby improving profit margins.
Geographic Expansion: Entering new markets can increase overall sales volume.
Product Lifecycle: Like all pharmaceutical products, CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER will experience phases of growth, maturity, and potential decline, influenced by new product introductions and evolving clinical practices.

Estimated Market Size and Growth (Global PN Market): While specific revenue figures for CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER are proprietary, the global parenteral nutrition market is substantial. Market research reports estimate the global parenteral nutrition market to be valued in the tens of billions of U.S. dollars and projected to grow at a compound annual growth rate (CAGR) of approximately 5-7% over the next five to seven years [1, 2]. This growth is underpinned by the increasing prevalence of conditions requiring PN and the expanding application of HPN. CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER's financial trajectory will be a function of its market share within this growing segment, particularly its ability to capture the sulfite-sensitive patient population and its cost-competitiveness against other PN components.

What are the Regulatory and Reimbursement Considerations?

Regulatory approval and reimbursement policies are critical determinants of a pharmaceutical product's market access and financial viability.

Regulatory Landscape: CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, as a parenteral nutrition product, is subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Manufacturing Standards: Facilities must comply with Current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and consistency.
Labeling Requirements: Accurate and comprehensive labeling is mandated, including indications, contraindications, warnings, and drug interactions.
Post-Market Surveillance: Ongoing monitoring for adverse events and product quality issues is required.
Approval Process: Approval is based on demonstrated safety and efficacy, although for established components like dextrose and amino acids, the focus is often on formulation stability, purity, and the absence of harmful impurities like sulfites.

Reimbursement Considerations: Parenteral nutrition products are typically covered by health insurance plans, including government payers (e.g., Medicare, Medicaid in the U.S.) and private insurers.

Coding: Specific billing codes (e.g., HCPCS codes in the U.S.) are used for PN components and admixtures, impacting reimbursement rates.
Coverage Determinations: Payers make decisions on whether and how much to reimburse for PN therapy based on medical necessity.
DRG Payments: In hospital settings, PN costs may be bundled into Diagnosis-Related Group (DRG) payments, influencing a hospital's decision on which PN products to stock and use.
Home Parenteral Nutrition (HPN) Reimbursement: HPN often involves complex reimbursement structures covering the product, administration supplies, and clinical support services.
Cost-Effectiveness: Payers increasingly evaluate the cost-effectiveness of different treatment options, which can favor lower-cost generic alternatives unless a branded product offers significant clinical advantages or caters to a specific unmet need, such as sulfite sensitivity.

The sulfite-free nature of CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER is a key differentiator that can justify its use in specific patient populations, potentially influencing payer coverage decisions for those identified with sulfite allergies or sensitivities.

Key Takeaways

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER is a sulfite-free parenteral nutrition component targeting patients with specific sensitivities or contraindications.
Market growth drivers include an aging population, rising chronic disease rates, and advancements in infusion technology, alongside the expansion of home parenteral nutrition.
The patent landscape, particularly regarding novel formulations or manufacturing processes for sulfite-free products, is crucial for understanding market exclusivity and the potential for generic competition.
The competitive environment includes both branded and generic suppliers of PN components, with pricing, product differentiation (sulfite-free formulation), and supply chain reliability as key competitive factors.
The financial trajectory is influenced by sales volume, pricing strategies, manufacturing costs, and the overall growth of the parenteral nutrition market, which is estimated to be in the tens of billions of dollars globally.
Regulatory approval (FDA, EMA) mandates strict manufacturing and labeling standards, while reimbursement policies from government and private payers dictate market access and the product's financial viability.

Frequently Asked Questions

What specific concentrations of amino acids and dextrose does CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER provide? The "2.75/25" in the product name indicates specific concentrations. The 2.75 likely refers to a percentage concentration of amino acids (e.g., grams of amino acids per 100 mL), and 25 refers to the percentage concentration of dextrose (25 grams per 100 mL). Precise figures would be found on the product's official labeling or technical specifications.
How does the absence of sulfites benefit patients? Sulfites can trigger hypersensitivity reactions in some individuals, ranging from mild symptoms like hives to severe anaphylaxis. For patients with known sulfite allergies or sensitivities, using a sulfite-free PN formulation like CLINIMIX eliminates this risk, ensuring safer nutritional support.
What are the primary alternative products to CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER? Alternatives include other parenteral nutrition components with varying amino acid and dextrose concentrations, as well as products that may contain sulfites. Additionally, fully compounded ready-to-use PN admixtures serve as an alternative delivery method.
Are there any specific risks associated with the dextrose 25% concentration in this product? Dextrose 25% is a hypertonic solution and must be administered intravenously, typically in a central venous catheter to prevent phlebitis and thrombosis. High dextrose concentrations can also contribute to hyperglycemia, especially in patients with impaired glucose tolerance or diabetes. Careful monitoring of blood glucose levels is essential.
What is the typical shelf life of CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER in its original packaging? The shelf life of parenteral nutrition products is highly dependent on the specific formulation, manufacturing process, and storage conditions. It is typically determined by the manufacturer and indicated on the product packaging and accompanying documentation. Shelf lives for such products can range from several months to over a year under recommended storage conditions.

Citations

[1] Grand View Research. (2023). Parenteral Nutrition Market Size, Share & Trends Analysis Report By Product (Amino Acids, Vitamins, Carbohydrates, Minerals, Trace Elements, Fats), By Formulation (2-in-1, 3-in-1), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030. Grand View Research. Retrieved from https://www.grandviewresearch.com/industry-analysis/parenteral-nutrition-market

[2] Allied Market Research. (2023). Parenteral Nutrition Market By Type, Therapy, End User, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2022-2031. Allied Market Research. Retrieved from https://www.alliedmarketresearch.com/parenteral-nutrition-market

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER at DailyMed

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Clinimix 2.75/25 Sulfite Free In Dextrose 25% In Plastic Container, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

Pharmacology for CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

US Patents and Regulatory Information for CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER: Market Dynamics and Financial Trajectory